Centocor Ortho Biotech Services, L.L.C.
Quick facts
Phase 3 pipeline
- infliximab, etanercept
- infliximab infusion; AZA placebo caps · Immunology
Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby inhibiting the inflammatory response.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Centocor Ortho Biotech Services, L.L.C. portfolio CI brief
- Centocor Ortho Biotech Services, L.L.C. pipeline updates RSS
Frequently asked questions about Centocor Ortho Biotech Services, L.L.C.
What is Centocor Ortho Biotech Services, L.L.C.'s pipeline?
Centocor Ortho Biotech Services, L.L.C. has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include infliximab, etanercept, infliximab infusion; AZA placebo caps.
Related
- Sector hub: All tracked pharma companies